Korea's First Domestic Obesity Drug Challenges the 300,000 Won Price Wall

The 300,000 Won Line

A line has been drawn in Korean pharmacy windows. Not on paper, but in won — and it is reshaping what everyone in this market assumed was fixed.

Domestically produced GLP-1 obesity drugs have long been a fantasy in South Korea. When Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro dominate the prescription market, the real question has never been whether a Korean drug could work. It is whether one could undercut the duopoly on price without bleeding margin.

Hanmi Pharmaceutical (415,500 won, +16,500) is about to test that assumption.

Its drug, EPPE (epeglutamide), has received GIFT — the fast-track review designation reserved for global innovation products — from the Ministry of Food and Drug Safety. Based on the accelerated timeline, regulatory approval could come as early as October, with launch no later than year-end. The company has confirmed this timeline publicly. What it has not confirmed is the price.

That omission is deliberate. Executives inside Hanmi are divided, sources say, and the strategy is to avoid premature disclosure. But the direction of travel is clear: EPPE will aim to break the 300,000 won monthly price barrier that currently defines the lower end of the Korean GLP-1 market.

The Numbers That Matter

To understand the stakes, look at the price table.

Mounjaro in Seoul pharmacies averages 305,000 won per pack at the 2.5 mg starting dose, climbing to roughly 700,000 won at 15 mg. Wegovy ranges from the low 200,000 wons to just under 400,000 won depending on dose. Both are non-covered, non-insured drugs — meaning patients pay the full price out of pocket, month after month, often for years.

The 300,000 won mark is where Mounjaro begins. Industry observers expect EPPE to launch somewhere around half that level. Whether that is 150,000 won or 200,000 won remains an open question, but the intent is unmistakable: position EPPE as the affordable alternative without requiring patients to sacrifice the doctor’s prescription.

For context, the average hospital consultation fee in Seoul for obesity treatment is 21,570 won. The drug itself is where the cost lives — and where the duopoly has set the terms.

Why This Matters Beyond Korea

A domestic Korean obesity drug is not just a local story. It is a signal flare.

The global GLP-1 market is worth tens of billions and growing. Novo Nordisk and Eli Lilly control the vast majority of it, and their pricing power in individual markets is strong precisely because they face limited competition. When a manufacturer in a country that traditionally lags in innovative drug development — Korea’s track record in original small-molecule and biologic innovation outside biosimilars is modest — announces it can produce a GLP-1 drug at a fraction of the cost, two things happen.

First, otherAsian markets take note. Japan, Taiwan, and Thailand already struggle with access to obesity medications at prices comparable to Seoul. If Hanmi can sustain a Korean domestic price below 300,000 won and maintain supply reliability through local manufacturing, the company will have leverage in export negotiations. The source confirms this: industry insiders say Lilly and Novo Nordisk are watching EPPE’s pricing strategy closely, recognizing it could influence pricing policies across existing Asian markets.

Second, the narrative around Korean pharma shifts. For decades, the country has been known as a biosimilar powerhouse — copying off-patent molecules, not inventing new ones. EPPE changes the taxonomy. It is not a biosimilar to Wegovy. It is a novel GLP-1 analogue, developed domestically, with its own clinical data profile. Whether Hanmi replicates that model with other molecules is uncertain, but the precedent matters.

The Efficacy Question

Price is only half the story. The other half is whether EPPE delivers enough weight loss to win prescriptions.

Hanmi’s Phase 3 trial enrolled 448 adult Korean patients with obesity. After 40 weeks, the epeglutamide group lost an average of 9.75% of baseline body weight. Roughly 79% of treated patients lost at least 5%, and about half lost 10% or more.

Those numbers are respectable for a first-in-class domestic candidate. They are not yet in the same league as the global benchmarks: Wegovy produced 14.9% average weight loss in a 68-week trial, and Mounjaro achieved 16.0% to 22.5% across doses in a 72-week study. But direct comparison is misleading — trial durations, patient demographics, and dosing protocols differ across studies, and regulators do not treat head-to-head data as interchangeable.

What Hanmi is emphasizing instead is tolerability. The company says gastrointestinal side effects — nausea, vomiting — were relatively mild compared with the global GLP-1 class. EPPE uses a “LapsCover” slow-release technology designed to maintain drug levels more steadily. Hanmi is also exploring digital therapeutics integration, positioning EPPE not as a short-term weight-loss intervention but as part of a longer-term lifestyle management program.

Whether Korean patients and their doctors will accept that framing over the heavier-weight (literally) clinical data behind Wegovy and Mounjaro remains to be seen.

Who Wins, Who Loses

The winners, if EPPE launches at the expected price point, are Korean patients who have been paying full price for imported obesity drugs and Korean pharmacies that will gain a locally manufactured alternative with supply-chain advantages.

Hanmi wins if it can sustain production at a price that undercuts the duopoly while preserving margin. That depends on whether its domestic manufacturing cost structure is materially lower than importing finished product — a reasonable assumption given exchange-rate exposure and logistics costs embedded in the current pricing.

Novo Nordisk and Eli Lilly lose market share in Korea, at least initially. Whether they respond with price cuts is unclear, but industry consensus leans toward yes. One source told Chosun Biz that both companies are expected to adjust their Korean pricing strategies in response to EPPE’s entry.

The bigger risk falls on patients and prescribers who may perceive EPPE as the cheaper option but lack confidence in its long-term efficacy and safety profile. GLP-1 treatments require sustained use; a drug that works for three months and then causes intolerable side effects is worse than no drug at all.

What Comes Next

EPPE’s launch will test a specific hypothesis: that a Korean-developed, Korean-manufactured GLP-1 drug can capture meaningful market share through price alone, even against globally validated competitors with far larger clinical databases.

If it succeeds, the implications extend beyond Korea. Seoul could emerge as a niche player in innovative obesity drug development — not the next Switzerland or Boston, but a credible regional supplier for price-sensitive Asian markets. If it struggles, the lesson will be that brand trust and clinical data in this category are harder to displace than price competitiveness alone.

The next six months will show which it is.

One thing is already certain: the 300,000 won monthly price wall that has defined the Korean GLP-1 market is no longer immune. EPPE is aiming at it, and whether Hanmi breaks through depends on pricing courage, clinical confidence, and the patience of patients who have been waiting for an alternative.